
UroGen Pharma Ltd. – NASDAQ:URGN
UroGen Pharma Ltd. stock price today
UroGen Pharma Ltd. stock price monthly change
UroGen Pharma Ltd. stock price quarterly change
UroGen Pharma Ltd. stock price yearly change
UroGen Pharma Ltd. key metrics
Market Cap | 437.18M |
Enterprise value | 256.60M |
P/E | -1.92 |
EV/Sales | 6.74 |
EV/EBITDA | -2.53 |
Price/Sales | 5.55 |
Price/Book | -3.34 |
PEG ratio | -0.12 |
EPS | -3.40 |
Revenue | 84.30M |
EBITDA | -66.29M |
Income | -104.31M |
Revenue Q/Q | 9.24% |
Revenue Y/Y | 24.00% |
Profit margin | -287.38% |
Oper. margin | -206.73% |
Gross margin | 81.66% |
EBIT margin | -206.73% |
EBITDA margin | -78.64% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeUroGen Pharma Ltd. stock price history
UroGen Pharma Ltd. stock forecast
UroGen Pharma Ltd. financial statements
$25
Potential upside: 31.92%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 21.13M | -24.13M | -114.18% |
---|---|---|---|
Sep 2023 | 20.85M | -21.87M | -104.93% |
Dec 2023 | 23.53M | -26.01M | -110.57% |
Mar 2024 | 18.78M | -32.28M | -171.91% |
Jun 2023 | 95361000 | 233.79M | 245.17% |
---|---|---|---|
Sep 2023 | 193633000 | 235.62M | 121.69% |
Dec 2023 | 178311000 | 243.52M | 136.57% |
Mar 2024 | 200574000 | 240.70M | 120.01% |
Jun 2023 | -20.27M | 3.72M | 143K |
---|---|---|---|
Sep 2023 | -17.29M | 401K | 116.07M |
Dec 2023 | -13.05M | -10.98M | 40K |
Mar 2024 | -31.73M | 13.51M | 54.65M |
UroGen Pharma Ltd. alternative data
Aug 2023 | 194 |
---|---|
Sep 2023 | 193 |
Oct 2023 | 193 |
Nov 2023 | 193 |
Dec 2023 | 192 |
Jan 2024 | 192 |
Feb 2024 | 192 |
Mar 2024 | 198 |
Apr 2024 | 198 |
May 2024 | 198 |
Jun 2024 | 204 |
Jul 2024 | 204 |
UroGen Pharma Ltd. other data
Period | Buy | Sel |
---|---|---|
Aug 2023 | 0 | 3800 |
Jan 2024 | 0 | 8782 |
Feb 2024 | 0 | 8782 |
Mar 2024 | 0 | 12000 |
Jun 2024 | 0 | 5153 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | SCHOENBERG MARK officer: Chief Me.. | Ordinary Shares | 10,000 | N/A | N/A | ||
Sale | SCHOENBERG MARK officer: Chief Me.. | Ordinary Shares | 5,153 | $13.08 | $67,401 | ||
Option | SCHOENBERG MARK officer: Chief Me.. | Restricted Stock Units | 10,000 | N/A | N/A | ||
Sale | SCHOENBERG MARK officer: Chief Me.. | Ordinary Shares | 12,000 | $14.05 | $168,600 | ||
Sale | SMITH JASON DREW officer: General .. | Ordinary Shares | 3,328 | $15.78 | $52,516 | ||
Sale | SMITH JASON DREW officer: General .. | Ordinary Shares | 3,328 | $15.78 | $52,516 | ||
Sale | SMITH JASON DREW officer: General .. | Ordinary Shares | 1,248 | $15.78 | $19,693 | ||
Sale | SMITH JASON DREW officer: General .. | Ordinary Shares | 1,248 | $15.78 | $19,693 | ||
Sale | SMITH JASON DREW officer: General .. | Ordinary Shares | 417 | $15.78 | $6,580 | ||
Sale | SMITH JASON DREW officer: General .. | Ordinary Shares | 417 | $15.78 | $6,580 |
Patent |
---|
Application Filling date: 9 Dec 2021 Issue date: 30 Jun 2022 |
Application Filling date: 31 Dec 2021 Issue date: 21 Apr 2022 |
Grant Utility: Connectable catheter Filling date: 25 Jun 2015 Issue date: 4 May 2021 |
Application Filling date: 31 Aug 2020 Issue date: 24 Dec 2020 |
Application PHARMACEUTICAL COMPOSITIONS COMPRISING IMIQUIMOD FOR USE IN THE TREATMENT OF CARCINOMA IN SITU OF THE BLADDER Filling date: 4 Oct 2019 Issue date: 3 Sep 2020 |
Grant Filling date: 11 Mar 2019 Issue date: 1 Sep 2020 |
Application Filling date: 22 Jul 2019 Issue date: 16 Apr 2020 |
Grant Filling date: 15 Oct 2013 Issue date: 12 Nov 2019 |
Quarter | Transcript |
---|---|
Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Ms. Elizabeth A. Barrett (1962) Pres, Chief Executive Officer & Director | $1,150,000 |
Dr. Mark P. Schoenberg (1958) Chief Medical Officer | $479,940 |
Mr. Jason Drew Smith (1972) Gen. Counsel & Chief Compliance Officer | $338,530 |
Ms. Molly Henderson CPA, MBA (1971) Chief Financial Officer | $279,340 |
UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation
UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either
UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy
UroGen: Upcoming PDUFA, Some Concerns Remain
UroGen Pharma's Financial And Clinical Symbiosis
UroGen: Struggling With Revenue And With Cash Runway
UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain
-
What's the price of UroGen Pharma Ltd. stock today?
One share of UroGen Pharma Ltd. stock can currently be purchased for approximately $18.95.
-
When is UroGen Pharma Ltd.'s next earnings date?
Unfortunately, UroGen Pharma Ltd.'s (URGN) next earnings date is currently unknown.
-
Does UroGen Pharma Ltd. pay dividends?
No, UroGen Pharma Ltd. does not pay dividends.
-
How much money does UroGen Pharma Ltd. make?
UroGen Pharma Ltd. has a market capitalization of 437.18M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 28.52% to 82.71M US dollars.
-
What is UroGen Pharma Ltd.'s stock symbol?
UroGen Pharma Ltd. is traded on the NASDAQ under the ticker symbol "URGN".
-
What is UroGen Pharma Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of UroGen Pharma Ltd.?
Shares of UroGen Pharma Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are UroGen Pharma Ltd.'s key executives?
UroGen Pharma Ltd.'s management team includes the following people:
- Ms. Elizabeth A. Barrett Pres, Chief Executive Officer & Director(age: 63, pay: $1,150,000)
- Dr. Mark P. Schoenberg Chief Medical Officer(age: 67, pay: $479,940)
- Mr. Jason Drew Smith Gen. Counsel & Chief Compliance Officer(age: 53, pay: $338,530)
- Ms. Molly Henderson CPA, MBA Chief Financial Officer(age: 54, pay: $279,340)
-
How many employees does UroGen Pharma Ltd. have?
As Jul 2024, UroGen Pharma Ltd. employs 204 workers, which is 3% more then previous quarter.
-
When UroGen Pharma Ltd. went public?
UroGen Pharma Ltd. is publicly traded company for more then 8 years since IPO on 4 May 2017.
-
What is UroGen Pharma Ltd.'s official website?
The official website for UroGen Pharma Ltd. is urogen.com.
-
Where are UroGen Pharma Ltd.'s headquarters?
UroGen Pharma Ltd. is headquartered at 400 Alexander Park, Princeton, NJ.
-
How can i contact UroGen Pharma Ltd.?
UroGen Pharma Ltd.'s mailing address is 400 Alexander Park, Princeton, NJ and company can be reached via phone at +64 6 768 9780.
-
What is UroGen Pharma Ltd. stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for UroGen Pharma Ltd. in the last 12 months, the avarage price target is $25. The average price target represents a 31.92% change from the last price of $18.95.
UroGen Pharma Ltd. company profile:

UroGen Pharma Ltd.
urogen.comNASDAQ
217
Biotechnology
Healthcare
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Princeton, NJ 08540
CIK: 0001668243
ISIN: IL0011407140
CUSIP: M96088105